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Persistent Recovery of Normal Left Ventricular Function and
Dimension in Idiopathic Dilated Cardiomyopathy During Long-Term
Follow-up: Does Real Healing Exist?
Marco Merlo, MD; Davide Stolfo, MD; Marco Anzini, MD; Francesco Negri, MD; Bruno Pinamonti, MD; Giulia Barbati, PhD;
Federica Ramani, PhD; Andrea Di Lenarda, MD; Gianfranco Sinagra, MD, FESC
Background-—An important number of patients with idiopathic dilated cardiomyopathy have dramatically improved left ventricular
function with optimal treatment; however, little is known about the evolution and long-term outcome of this subgroup, which shows
apparent healing. This study assesses whether real healing actually exists in dilated cardiomyopathy .
Methods and Results-—Persistent apparent healing was evaluated among 408 patients with dilated cardiomyopathy receiving
tailored medical treatment and followed over the very long-term. Persistent apparent healing was deﬁned as left ventricular
ejection fraction ≥50% and indexed left ventricular end-diastolic diameter ≤33 mm/m2 at both mid-term (194 months)
and long-term (1039 months) follow-up. At mid-term, 63 of 408 patients (15%) were apparently healed; 38 (60%; 9%
of the whole population) showed persistent apparent healing at long-term evaluation. No predictors of persistent apparent
healing were found. Patients with persistent apparent healing showed better heart transplant–free survival at very long-term
follow-up (95% versus 71%; P=0.014) compared with nonpersistently normalized patients. Nevertheless, in the very long
term, 37% of this subgroup experienced deterioration of left ventricular systolic function, and 5% died or had heart
transplantation.
Conclusions-—Persistent long-term apparent healing was evident in a remarkable proportion of dilated cardiomyopathy patients
receiving optimal medical treatment and was associated with stable normalization of main clinical and laboratory features. This
condition can be characterized by a decline of left ventricular function over the very long term, highlighting the relevance of serial
and individualized follow-up in all patients with dilated cardiomyopathy, especially considering the absence of predictors for long-
term apparent healing. ( J Am Heart Assoc. 2015;4:e001504 doi: 10.1161/JAHA.114.001504)
Key Words: cardiac remodeling • dilated cardiomyopathy • heart failure
I diopathic dilated cardiomyopathy (DCM) is a rare primaryheart muscle disease with genetic, infective, and autoim-
mune etiologies that is characterized by progressive loss of
cardiomyocytes and progression to end-stage cardiac failure.1
It generally affects relatively young patients with low comor-
bidity proﬁles and, theoretically, long life expectancy.2 Conse-
quently, DCM represents a peculiar model of heart failure (HF)
with substantial differences from other etiologies (ie, ischemic,
hypertensive, and valvular heart disease) that more commonly
affect the elderly population. The prognosis of DCM,
considered ominous in the past,3 has improved progressively
over the past 2 decades as the result of an integrated strategy
based on evidence-based therapy, early diagnosis, and struc-
tured follow-up.4,5 Although some patients with DCM are still
projected to have a severe outcome soon after diagnosis, most
now show favorable long-term survival, usually associated with
left ventricular (LV) reverse remodeling.5,6 Recently, persistent
recovery of LV function during long-term follow-up has been
demonstrated in >70% of patients with HF from different
etiologies that initially improved with b-blockers7; however,
the real prevalence and exhaustive long-term characterization
of apparently healed patients under medical treatment,
particularly in the speciﬁc setting of DCM, remain unknown.
Few data are reported in the literature, which is limited to small
and not optimally treated populations.8
In the present study, we analyzed the prevalence of
persistent normalization of LV function and dimension in a
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broad cohort of patients with DCM receiving optimal medical
treatment. We carefully described the clinical and instrumen-
tal evolution during very long-term regular follow-up to assess
whether a real healing phenomenon might exist in this
progressive disease. Furthermore, we sought to identify the
early predictors of this peculiar condition.
Methods
In this observational retrospective study, we speciﬁcally
investigated patients with DCM with persistent apparent
healing conditions (deﬁned in Study Design) among those
consecutively enrolled in the Heart Muscle Disease Registry
of Trieste, a database from a tertiary referral center for
cardiomyopathies and HF, from January 1988 to December
2003. The follow-up ended at the time of death or urgent
(status I) heart transplant (HTx) or at December 31, 2011, in
the absence of main events; therefore, the study population
had potential clinical follow-up of at least 8 years. Informed
consent was obtained from all subjects under the institutional
review board policies of the Trieste Hospital administration.
All patients underwent a structured serial clinical and
instrumental follow-up evaluation at the Cardiomyopathy
Clinic of the Cardiovascular Department of Trieste at 6
months (range: 3 to 8), 12 months (range: 9 to 18), and 24
months (range: 19 to 36) and then every 2 years or according
to speciﬁc clinical needs.
DCM diagnosis was deﬁned according to the World Health
Organization criteria.9 Patients with LV systolic dysfunction
(LV ejection fraction [LVEF] <50%) at baseline evaluation in
the absence of known causes were included in the registry.
Exclusion criteria were history of blood pressure >160/
100 mm Hg, >50% obstruction of a major coronary artery
branch (at coronary angiography), alcohol intake >100 g/day,
advanced systemic disease affecting short-term prognosis,
pericardial diseases, congenital heart diseases, HF secondary
to chronic lung disease, and biopsy-proven active myocarditis.
Persistent, high-rate, supraventricular arrhythmias were con-
sidered as an exclusion criterion when documented in the
6 months before enrollment; however, patients with persis-
tent LV systolic dysfunction 6 months after the resolution of
the arrhythmia were enrolled in the registry and included in
the analysis. All familial DCM cases fulﬁlled the published
criteria.10
At enrollment, all patients underwent an accurate clinical
history interview, a complete physical examination, blood
sampling for laboratory tests, 12-lead electrocardiogram, and
echocardiographic and Doppler evaluation. Coronary angiog-
raphy was performed in patients aged >35 years with
cardiovascular risk factors and/or without familial history of
DCM. Until 1996, all patients underwent endomyocardial
biopsy to exclude active myocarditis according to the Dallas
criteria.11 Thereafter, biopsy was performed in patients with
recent-onset HF refractory to conventional therapy, severe
LV systolic dysfunction, and/or unexplained life-threatening
ventricular arrhythmias and a clinical history suggesting active
myocarditis in the absence of marked LV dilation and LV
bundle-branch block.12,13
According to our internal protocol since 1988, after careful
clinical stabilization on an optimal dose of angiotensin-
converting enzyme (ACE) inhibitors or angiotensin receptor
blockers, all patients without contraindications or hemody-
namic impairment (85% of study population) were treated with
b-blockers (metoprolol tartrate and, later, carvedilol or
bisoprolol) and received diuretics and digitalis if clinically
indicated. Daily dosages of ACE inhibitors and b-blockers are
reported as equivalent to enalapril and carvedilol, respectively
(enalapril-equivalent dosages: captopril 93.75 mg; lisinopril
91 mg; carvedilol-equivalent dosages: metoprolol/2 mg,
bisoprolol 910)14 and refer to the end of the titration period
(generally 1 to 3 months after enrollment). Moreover,
according to preliminary data from our registry and the
published evidence on secondary prevention of sudden
death,15–17 the use of an implanted cardioverter-deﬁbrillator
for primary prevention started in 1998 for patients with DCM
who matched high-risk criteria for sudden death (persistent
LVEF ≤35% and New York Heart Association [NYHA] classes II
and III despite optimal treatment). Device implantation for
cardiac resynchronization therapy started in 2005, after
publication of the CARE-HF trial.18
Echocardiographic Study
Comprehensive M-mode, 2-dimensional, and Doppler echo-
cardiographic studies were performed at baseline and at mid-
term and long-term follow-up. Systolic and diastolic functions
were evaluated according to international guidelines.19 Right
ventricular areas and fractional area contraction and the end-
systolic left atrial area were measured with the same
approach. Mitral regurgitation was semiquantitatively graded
considering the regurgitant jet area at color Doppler imaging
and/or the vena contracta width.20 Mitral regurgitations with
jet area >4 cm2 and vena contracta ≥0.4 cm were considered
signiﬁcant.
The transmitral ﬂow velocity curve was obtained by pulsed
Doppler imaging, positioning the sample volume between the
tips of the mitral leaﬂets; the LV ﬁlling pattern was classiﬁed
as restrictive in the presence of E-wave deceleration time
<120 ms or E/A ≥2 associated with E-wave deceleration time
≤150 ms.21 For patients with atrial ﬁbrillation, only data from
the E wave were considered. All measurements were obtained
from the mean of 3 beats for the patients with sinus rhythm
and 5 beats for those with atrial ﬁbrillation. Chamber
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diameters, areas, and volumes were normalized for body
surface area. Reproducibility of Doppler echocardiographic
data in our echo laboratory has been published previously.21
Study Design
Apparent healing was deﬁned as the combined presence at
mid-term follow-up (mean 194 months) of normal LVEF
(≥50%) and normal indexed LV end-diastolic diameter
(≤33 mm/m2). Apparent healing was considered persistent
if the normalization of both LV function and dimension were
maintained at long-term follow-up (mean 1039 months).
The primary outcome measure was either death or urgent
HTx. The indication for HTx was considered in patients with
refractory HF requiring inotropic treatment and/or mechan-
ical support (status I). Information regarding the end points
was obtained directly from the patient, from the patient’s
physician, or from the register of death for the municipality of
residence.
Statistical Analysis
Summary statistics of clinical and instrumental variables were
expressed as mean and SD or percentage, as appropriate.
Comparisons between groups were made using the ANOVA
test with continuous variables and the Brown-Forsythe
statistic if the assumption of equal variances did not hold;
the chi-square test was calculated for discrete variables.
General survival for death or HTx was calculated by the
Kaplan–Meier method, and the log-rank test was used to
assess differences among groups. To ﬁnd prognostic factors
for the persistent apparent healing condition, univariable
logistic regression models were estimated. All calculations
were performed using IBM SPSS 19.0 for Windows (IBM Corp)
and R statistical software version 2.15.0 (R Foundation).
Results
Persistent Apparent Healing: Prevalence and
Characterization
The apparent healing condition was found in 63 patients,
representing 15% of the initial population of 408 patients with
DCM with available baseline and follow-up data. Before
enrollment, only 45% of patients were treated with ACE
inhibitors or angiotensin receptors blockers and 16% were
treated with b-blockers; after our ﬁrst evaluation, they were
optimally treated with ACE inhibitors (or angiotensin receptor
blockers) and b-blockers (95% with the equivalent dosage of
enalapril of 1812 mg/day and 85% with the equivalent
dosage of carvedilol of 4625 mg/day, respectively) without
signiﬁcant differences between apparently healed patients at
mid-term and the non-apparently healed patients at mid-term.
Optimal medical treatment was maintained over follow-up
(90% and 81% were treated with ACE inhibitors and b-
blockers, respectively, after mid-term follow-up).
Apparently healed patients showed signiﬁcantly better
long-term survival (P<0.001) than patients who were not
apparently healed and alive at mid-term (42 patients died or
underwent urgent HTx before mid-term follow-up) (Figure 1).
Persistent apparent healing at long-term follow-up was
detected in 38 of 63 patients (60% of those apparently healed;
9% of the whole population). Before the long-term evaluation,
4 of 63 patients (10%) died (1 death for HF, 1 sudden death,
1 death for unknown cause) or underwent HTx (1 case)
(Figure 2). Patients with persistent long-term recovery of
LVEF and LV end-diastolic diameter less frequently presented
signiﬁcant mitral regurgitation at baseline compared with the
nonpersistently apparently healed patients (17% versus 45%,
respectively; P=0.022). No other baseline and mid-term
clinical and laboratory differences emerged between the 2
groups (Table 1). At univariate analysis, no baseline and mid-
term parameters emerged as predictors of persistent appar-
ent healing at long-term follow-up (Table 2); therefore,
subsequent multivariate analyses were not performed.
Long-Term Temporal Trends of Main Clinical and
Laboratory Features
Figure 3 shows the longitudinal trends of main clinical and
laboratory features (ie, patients in NYHA class I, LVEF, indexed
LV end-diastolic diameter, indexed LV end-diastolic volume,
signiﬁcant mitral regurgitation, LV restrictive ﬁlling pattern)
Figure 1. Kaplan–Meier curves for very long-term heart trans-
plant-free survival of patients who were apparently healed and not
apparently healed and alive at mid-term. Dotted lines represent
apparently healed patients; solid lines represent patients who
were not apparently healed. HTx indicates heart transplant.
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during the structured long-term follow-up in the 38 persis-
tently apparently healed and 21 nonpersistently normalized
patients. In the ﬁrst subgroup, all parameters reached
normalization at 24 months and were maintained at long-
term evaluation. Conversely, nonpersistently normalized
patients satisﬁed the apparent healing criteria at mid-term
but later showed progressive worsening of clinical and
echocardiographic parameters, usually starting from the ﬁfth
year of follow-up, with the exception of LVEF, which dramat-
ically decreased after the 24th month of follow-up.
Persistent Apparent Healing Condition: Very
Long-Term Prognostic Assessment
During very long-term follow-up of 18056 months, persis-
tently apparently healed patients showed better outcomes
with respect to nonpersistently healed patients (95% versus
71% HTx-free survival; P=0.014) (Figure 4). Interestingly, at
the last echocardiogram, 14 of 38 persistently apparently
healed patients (37%) showed systolic dysfunction (LVEF
<50%), and 12 (32%) presented increased LV dimensions (LV
end-diastolic diameter >33 mL/m2). At very long-term follow-
up, 2 of 38 patients with persistent apparent healing (5%) died
or underwent HTx (1 thromboembolic death and 1 death from
HF), both presenting normal LVEF but increased LV end-
diastolic diameter at the last available echocardiogram
compared with 6 of 21 nonpersistently apparently healed
patients (29%; 1 death from HF, 1 sudden death, 1 death from
unknown cause, 3 HTx). Moreover, at very long-term follow-
up, 2 of 38 patients (5%) who were persistently apparently
healed (at 17525 months) and 5 of 21 patients (24%) who
were nonpersistently apparently healed (at 17359 months)
underwent implanted cardioverter-deﬁbrillator and/or cardiac
resynchronization therapy implantation for severe deteriora-
tion of LVEF (Figure 2).
Discussion
It is becoming clear that DCM represents not the irrevers-
ible consequence of a cardiomyopathic process but rather a
dynamic model with evolution that is highly variable
and able to be changed by optimized pharmacological and
nonpharmacological treatments.5,22,23 Nevertheless, accu-
rate information regarding the long-term characterization
Figure 2. Flowchart of the long-term evolution of the study population. All analyzed patients underwent a complete echocardiographic
evaluation at each follow-up. CRT indicates cardiac resynchronization therapy; HTx, heart transplant; ICD, implantable cardioverter-deﬁbrillator.
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and prognosis of “super-responders” to optimal treatment in
this peculiar model of HF are lacking. This study provides
this information. The population of 38 persistently appar-
ently healed patients with DCM is only apparently small; in
fact, this group derives from an initial population of 408
patients with DCM of whom 63 (15%) experienced normal-
Table 1. Baseline and mid-term Clinical and Laboratory Characteristics of Persistent Apparently Healed Vs Nonpersistently
Apparently Healed Patients
Persistently Apparently
Healed Patients (n=38)
Nonpersistently Apparently
Healed Patients (n=21) P Value
Parameters at baseline
Age at diagnosis, y 4213 423 0.940
Male, % 74 81 0.401
Familial DCM, % 16 24 0.449
Duration of HF, months 511 917 0.20
SBP, mm Hg 12714 13216 0.215
Heart rate, beats/min 8018 7712 0.442
NYHA classes III to IV, % 24 19 0.681
Serum Hb, g/dL 14.01.6 14.61.6 0.286
Serum creatinine, mg/dL 1.100.19 1.130.17 0.700
Sinus rhythm, % 90 100 0.133
LBBB, % 13 25 0.256
LAAI, cm2/m2 124 124 0.580
LVEF, % 3610 3613 0.901
LVEDDI, mm/m2 334 334 0.957
LVEDVI, mL/m2 8427 9439 0.308
RFP, % 18 30 0.315
Significant MR, % 17 45 0.022
b-blockers after first evaluation, % 84 86 0.878
ACEi/ARBs after first evaluation, % 82 95 0.142
Parameters at mid-term follow-up
SBP, mm Hg 12714 1269 0.775
Heart rate, beats/min 649 669 0.562
NYHA class II (vs NYHA class I), % 23 18 0.666
Serum Hb, g/dL 13.01.7 15.30.5 0.52
Sinus rhythm, % 94 94 1.00
LBBB, % 11 11 1.00
LAAI, cm2/m2 113 112 0.725
LVEF, % 533 544 0.649
LVEDDI, mm/m2 294 283 0.755
LVEDVI, mL/m2 6114 6618 0.277
RFP, % 0 6 0.153
Significant MR, % 0 6 0.147
b-blockers after midterm evaluation, % 82 81 0.953
ACEi/ARBs after midterm evaluation, % 90 90 0.908
ACEi indicates angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; Hb, haemoglobin; HF, heart failure; LAAI, indexed left atrial area; LBBB, left bundle-branch
block; LVEDDI, indexed left ventricular end-diastolic diameter; LVEDVI, indexed left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; NYHA,
New York Heart Association; RFP, restrictive ﬁlling pattern; SBP, systolic blood pressure.
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ized LV function and dimension under optimal medical
treatment. To our knowledge, this DCM population is the
largest with the longest follow-up focusing on the recovery
of normal LV function and dimension in response to medical
treatment.
Persistent Apparent Healing Condition in Long-
Term Follow-up
After an adequate period of optimal medical therapy (almost
2 years), 15% of patients with DCM in our study showed
apparent healing and more favorable long-term outcomes.
These ﬁndings are only partially surprising because they are
consistent with the well-known effectiveness of ACE inhibi-
tors, b-blockers, and aldosterone antagonists in inducing LV
reverse remodeling in more than one third of patients with
DCM at mid-term5,24 and subsequently higher long-term
survival directly related to the amount of LV systolic function
and improvement in size (Figure 1). Moreover, this study
probably underestimated the magnitude of the apparent
healing phenomenon. To assess the characterization of
persistent long-term apparent healing in DCM, enrollment
ended in 2003. Consequently, only a minority (2%) of the
whole initial population underwent cardiac resynchronization
therapy implantation in the ﬁrst 2 years of follow-up; however,
the possibility of LVEF normalization in a subgroup of patients
with DCM after cardiac resynchronization therapy implanta-
tion is widely described in literature, and future studies are
needed to characterize this subgroup of patients during long-
term follow-up.25
The most surprising and novel results of the present study
concern the long-term characterization of the apparent
healing phenomenon in DCM, in particular, (1) the demon-
stration of long-term persistence (at least 8 years; mean
follow-up: 18056 months) of an apparent healing condition in
60% of normalized patients at mid-term, representing almost
Table 2. Univariable Analysis: Baseline and Mid-term Predictors of a Persistent Apparent Healing Condition
OR CI 95% P Value
Parameters at baseline
Age (for 1-year increase) 0.999 0.966 to 1.032 0.940
Male sex 0.646 0.232 to 1.797 0.403
HF duration (for 1-month increase) 0.982 0.949 to 1.016 0.296
NYHA class (for 1-class increase) 1.034 0.634 to 1.684 0.894
SBP (for 1-mm Hg increase) 0.985 0.954 to 1.018 0.364
LVEF (for 1-unit increase) 0.993 0.951 to 1.038 0.767
LAAI (for 1-cm2/m2 increase) 0.964 0.848 to 1.083 0.533
LVEDDI (for 1-mm/m2 increase) 0.997 0.983 to 1.011 0.683
LVEDVI (for 1-mL/m2 increase) 1.016 0.918 to 1.124 0.761
RFP 0.835 0.284 to 2.454 0.744
Significant MR 0.375 0.129 to 1.089 0.071
LBBB 0.640 0.195 to 2.100 0.461
b-blockers 1.231 0.396 to 3.825 0.720
ACEi/ARBs 0.403 0.108 to 1.495 0.174
Parameters at midterm follow-up
NYHA class (for 1-class increase) 1.354 0.435 to 4.220 0.601
SBP (for 1-mm Hg increase) 0.995 0.956 to 1.035 0. 799
LVEF (for 1-unit increase) 0.948 0.881 to 1.021 0.158
LAAI (for 1-cm2/m2 increase) 0.904 0.740 to 1.104 0. 321
LVEDDI (for 1-mm/m2 increase) 1.071 0.924 to 1.241 0.644
LVEDVI (for 1-mL/m2 increase) 0.994 0.963 to 1.025 0.686
Significant MR 0.811 0.384 to 1.715 0.584
LBBB 1.094 0.252 to 4.740 0.905
ACEi indicates angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; HF, heart failure; LAAI, indexed left atrial area; LBBB, left bundle-branch block; LVEDDI,
indexed left ventricular end-diastolic diameter; LVEDVI, indexed left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; NYHA, New York Heart
Association; OR, odds ratio; RFP, restrictive ﬁlling pattern; SBP, systolic blood pressure.
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10% of the whole DCM population; (2) the evidence in these
patients of a concomitant persistent normalization of other
important clinical and echocardiographic features mostly
induced by long-term optimal medical therapy; (3) the
absence of baseline and mid-term predictors of a persistent
apparent healing condition; and (4) the need for continuous,
individualized, and probably lifelong follow-up and optimal
treatment also for persistently normalized patients with DCM,
considering the high frequency (>30%) of deterioration of LV
size and systolic function and non-negligible rates (5%) of
death or HTx at very long-term follow-up in this subgroup. In
our opinion, the latter results support the absence of real
healing in DCM. In this sense, the apparent healing condition
appears to be a phenomenon driven by optimal medical
treatment rather than by natural healing (there is no active
myocarditis in our population). There is a need for further
imaging and molecular studies26,27 to investigate the unex-
plored mechanisms underlying the possibly real healing
phenomenon in DCM.
Long-Term Temporal Trends of Main Clinical and
Laboratory Features and Prognostic Assessment
Interestingly, before long-term evaluation, 24% of patients
with an initial apparent healing condition worsened progres-
sively over the course of the disease, and 5% died or
underwent HTx. The main clinical and echocardiographic
features of these patients showed stable values in the ﬁrst
3 years after initial normalization, with a subsequent progres-
sive decline. This highlights the frequently degenerative nature
of DCM over the long-term despite pharmacological and
nonpharmacological integrated evidence-based therapy. Nota-
bly, LVEF was the ﬁrst parameter that declined after the initial
transient normalization. For this reason, LVEF might represent
the most important parameter for periodic assessment of
these patients during follow-up because it could precede the
unfavorable evolution of other clinical and instrumental
features, such as progressive LV remodeling, signiﬁcant mitral
regurgitation, and severe diastolic dysfunction.
Figure 3. Longitudinal long-term trends of main clinical and laboratory features in patients who were persistently apparently healed and
nonpersistently apparently healed. All analyzed patients underwent a complete echocardiographic evaluation at each follow-up. Solid lines
represent persistently apparently healed patients; broken lines represent nonpersistently apparently healed patients. iLVEDD indicates indexed
left ventricular end-diastolic diameter; iLVEDV, indexed left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVRFP, left
ventricular restrictive ﬁlling pattern; MR, mitral regurgitation; NYHA, New York Heart Association.
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The present study failed to identify predictors of long-term
persistent apparent healing among the more commonly
evaluated parameters both at baseline and at mid-term, as
conﬁrmed by the lack of signiﬁcant differences in clinical and
laboratory features for patients who were persistently and
nonpersistently apparently healed (Table 2). It is possible that
follow-up of 24 months represents too short a period in which
to assess the likelihood of long-term persistent apparent
healing; however, this ﬁnding conﬁrms the complexity of
prognostic stratiﬁcation of DCM that has recently emerged in
other experiences.28 DCM represents an extremely varied
disease in terms of etiopathogenesis, clinical presentation,
and evolution. In this sense, accurate and individualized long-
term surveillance over time (probably lifelong) together with
administration of optimal medical treatment from initial
diagnosis remain the cornerstones for appropriate manage-
ment of patients with DCM. Consequently, we strongly
suggest that a serial echocardiographic assessment of
patients with DCM be performed independently from varia-
tions in clinical conditions.29 This management could allow
identiﬁcation of patients at higher risk of disease progression
and set the correct timing for aggressive nonpharmacolo-
gical interventions. Future studies are needed to investigate
the individual genetic background of response to medical
treatment.
Notably, no sudden death or implanted cardioverter-
deﬁbrillator interventions were reported in the 8 patients
with transient apparent healing who underwent primary-
prevention implanted cardioverter-deﬁbrillator implantation
during long-term follow-up (Figure 2). In our opinion, this
interesting aspect further highlights the lack of solid criteria
for early arrhythmic risk stratiﬁcation, which represents a
major issue in the management of patients with DCM,
particularly in the ﬁrst years of follow-up.28,30 Future studies
focused speciﬁcally on this issue are needed.
Study Limitations
This observational retrospective study of long-term registry
data suffers from the common bias of different protocols and
treatment; however, the presence of the same inclusion
criteria over time at the same institution could represent an
advantage for the present analysis. Furthermore, the study
population was enrolled in a tertiary referral center for
cardiomyopathies and HF, imposing a selection bias with
respect to the characteristics of DCM in the general
population.
The deﬁnitions of mid-term (about 2 years after enroll-
ment), long-term (about 8 years after enrollment), and very
long-term (about 15 years after enrollment) follow-up were
arbitrary. There is no speciﬁc guideline or clear evidence on
this topic, thus we set the timing of follow-up based on our
clinical experience and previous reports.2,5
According to recommendations, endomyocardial biopsy
has not been performed systematically in our patients with
DCM since 199712; however, we found similar prevalence of
apparently healed patients at mid-term before and after 1996
(19% and 21%, respectively; P=0.765).
Because the enrollment period ended in 2003, before the
results of large randomized studies, treatment with aldoste-
rone antagonists was not administered systematically in
symptomatic patients (NYHA class II or higher).29
No systematic information on genetic proﬁle, tissue
Doppler or speckle tracking echocardiography, cardiac mag-
netic resonance, and brain natriuretic peptide values was
available because many patients were enrolled before these
evaluations were performed routinely at our center.
We included HTx in the composite end point even though
it is not a fatal event. In our opinion, it remains a major
event in the evolution of DCM and has an impact similar to
death in the prognostic evaluation of the disease, especially
considering that only urgent HTx was performed in our
series.
Finally, our population included only patients with DCM;
therefore, these results should not be extended to patients
with other causes of impaired LVEF, such as hypertensive or
ischemic heart disease.
Clinical Implications and Conclusions
In optimally treated DCM, a remarkable number of patients
(60% of normalized patients at midterm; 9% of the initial
population) experienced persistent apparent healing during
long-term follow-up. This favorable condition was associated
Figure 4. Kaplan–Meier curves for very long-term heart trans-
plant-free survival of patients who were persistently apparently
healed vs nonpersistently apparently healed and alive at long-
term follow-up. HTx indicates heart transplant.
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with persistent normalization of main clinical and laboratory
parameters, but no early features emerged as being able to
predict the stability of the apparent healing condition.
Despite the apparent resolution of the disease, a non-
negligible proportion of patients died or had a worsened
clinical and instrumental condition over the very long-term.
These patients cannot be considered to be effectively healed
and should be carefully and systematically followed and
treated over the long-term to identify early clues of disease
progression.
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